In vitro and in vivo activities of meropenem and comparable antimicrobial agents against Haemophilus influenzae, including beta-lactamase-negative ampicillin-resistant strains

J Antimicrob Chemother. 2001 Nov;48(5):723-6. doi: 10.1093/jac/48.5.723.

Abstract

The in vitro activity of ampicillin, cefotaxime, meropenem, panipenem, imipenem and biapenem was assayed using ampicillin-susceptible, beta-lactamase-positive and beta-lactamase-negative ampicillin-resistant (BLNAR) Haemophilus influenzae isolated recently in Japan. Against ampicillin-susceptible isolates, cefotaxime was the most potent (MIC(90) 0.016 mg/mL). Both cefotaxime and meropenem (MIC(90) of both, 0.5 mg/L) were the most potent against beta-lactamase-positive isolates. Against BLNAR isolates, meropenem (MIC(90) 0.5 mg/L) was the most potent. In murine bronchopneumonia caused by ampicillin-susceptible and BLNAR H. influenzae, cefotaxime showed the best efficacy, followed by meropenem. Our results indicate that meropenem could be a useful intravenous agent for infections caused by H. influenzae, including BLNAR strains.

Publication types

  • Comparative Study

MeSH terms

  • Ampicillin Resistance*
  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Bronchopneumonia / drug therapy
  • Bronchopneumonia / enzymology
  • Bronchopneumonia / microbiology
  • Haemophilus Infections / drug therapy
  • Haemophilus Infections / enzymology
  • Haemophilus Infections / microbiology
  • Haemophilus influenzae / drug effects*
  • Haemophilus influenzae / enzymology
  • Haemophilus influenzae / isolation & purification
  • Humans
  • Meropenem
  • Mice
  • Thienamycins / pharmacology*
  • Thienamycins / therapeutic use
  • beta-Lactamases* / isolation & purification

Substances

  • Anti-Bacterial Agents
  • Thienamycins
  • beta-Lactamases
  • Meropenem